<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644954</url>
  </required_header>
  <id_info>
    <org_study_id>NK/1842/Res/1096</org_study_id>
    <nct_id>NCT02644954</nct_id>
  </id_info>
  <brief_title>Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis</brief_title>
  <official_title>Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis vulgaris is a common, chronic, relapsing skin disease characterized by predominant
      involvement of skin, nails and joints. Recent advances in its patho-physiology have shifted
      the notion of psoriasis from that of a 'disease of the skin' to a 'T-cell mediated systemic
      disease'. Better understanding of its pathogenesis and co-morbidities along with the
      development of novel therapeutics like biological response modifiers has changed the way
      dermatologists approach the management of psoriasis. Based on the extent of involvement and
      effect on the quality of life, psoriasis may be mild to moderate in severity. This in turn
      forms the basis of treatment in majority of the patients. Topical therapies like coal tar,
      calcipotriol and corticosteroids are sufficient for mild and localized psoriasis. In more
      widespread or severe forms that are associated with significant decrease in quality of life
      of patient, phototherapy and systemic therapies are indicated either alone or in combination
      with each other. Although the introduction of biological therapies has revolutionized the
      treatment of psoriasis in recent years, such newer therapeutic options continue to elude the
      vast majority of patients in the developing and under developed world where the traditional
      agents like methotrexate, cyclosporine, acitretin and phototherapy still form the backbone of
      treatment.

      The association of psoriasis with metabolic syndrome is now well documented. Metabolic
      syndrome is a cluster of risk factors including central obesity, atherogenic dyslipidemia,
      hypertension and glucose intolerance and is a strong predictor of cardiovascular diseases,
      diabetes and stroke. Metformin, an oral hypoglycemic agent of biguanide class is known for
      its multitude of action on various facets of metabolic syndrome. Recently it has also been
      found to inhibit keratinocyte proliferation in cell culture model of psoriasis.

      The present study is designed as a randomized controlled double blind pilot study in which 40
      patients with chronic plaque psoriasis of moderate severity (PASI ≥ 6 or DLQI ≥ 6) and
      metabolic syndrome (By modified ATP III criteria)4 or impaired glucose tolerance (defined as
      two-hour glucose levels of 140 to 199 mg per dL on the 75-g oral glucose tolerance test) will
      be recruited and randomized into two arms, A and B of 20 each, by using random number tables.
      Patients in arm A will be treated with topical anti-psoriatic treatment (including coal tar
      and vitamin D3 analogues only) and oral metformin 1g/day 850mg twice daily and patients in
      arm B will be treated with topical anti-psoriatic treatment and oral placebo tablets. Post
      randomization patients will be followed up at regular intervals for 24 weeks. During each
      visit, patients in both arms will be assessed for the severity of psoriasis by psoriasis
      activity severity index (PASI) and body mass index (BMI). Fasting blood glucose and insulin
      level, glycosylated haemoglobin (HbA1c) and parameters of metabolic syndrome (including waist
      circumference, fasting lipid profile and blood pressure) will be assessed at baseline and
      again at week 16 and 24. The primary aim of this study is to assess the efficacy and safety
      of oral metformin as an add on therapy for the treatment of chronic plaque psoriasis of
      moderate severity. The secondary aim is to assess the effect of metformin on parameters of
      the metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving 75% reduction in psoriasis activity severity index (PASI)</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the efficacy of oral metformin in chronic plaque psoriasis of moderate severity. The proportion of patients achieving PASI 75 assesses the efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving 90% reduction in psoriasis activity severity index (PASI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who show change in parameters of metabolic syndrome after taking metformin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical coal tar and topical calcipotriol + oral metformin 850mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical coal tar and topical calcipotriol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Coal tar</intervention_name>
    <description>Topical coal tar to be applied once daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical calcipotriol</intervention_name>
    <description>Topical calcipotriol to be applied once daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic plaque psoriasis of moderate severity, defined as PASI ≥ 6 and/or DLQI ≥ 6

          -  Metabolic syndrome (By modified ATP III criteria)4 or impaired glucose tolerance
             (defined as two-hour glucose levels of 140 to 199 mg per dL on the 75-g oral glucose
             tolerance test.)

        Exclusion Criteria:

          -  Known drug allergies to biguanides.

          -  Psoriatic arthritis

          -  Pustular psoriasis

          -  Severe psoriasis PASI&gt;10, DLQI&gt; 10

          -  Patient with overt diabetes mellitus, defined as fasting blood sugar &gt; 126mg/dl
             glucose tolerance test of &gt;200mg/dl.

          -  Intake of oral hypoglycemic or systemic anti-psoriatic medication within the last 4
             weeks.

          -  Patients on medications for cardiovascular, gastrointestinal, hepatic, renal,
             disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Dogra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sunil Dogra, MD</last_name>
    <email>sundogra@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarun Narang, MD</last_name>
    <email>narangtarun@yahoo.co.in</email>
  </overall_contact_backup>
  <reference>
    <citation>Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007 Dec;57(6):1059-68. Epub 2007 Aug 15. Review.</citation>
    <PMID>17706835</PMID>
  </reference>
  <reference>
    <citation>Li W, Ma W, Zhong H, Liu W, Sun Q. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med. 2014 Feb;7(2):389-392. Epub 2013 Nov 19.</citation>
    <PMID>24396411</PMID>
  </reference>
  <reference>
    <citation>Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:3-11. doi: 10.1111/j.1468-3083.2011.04410.x. Review.</citation>
    <PMID>22356630</PMID>
  </reference>
  <reference>
    <citation>Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008 Aug;159 Suppl 2:10-7. doi: 10.1111/j.1365-2133.2008.08780.x. Review.</citation>
    <PMID>18700910</PMID>
  </reference>
  <reference>
    <citation>Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007 Jul;157(1):68-73. Epub 2007 Jun 6.</citation>
    <PMID>17553036</PMID>
  </reference>
  <reference>
    <citation>Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41.</citation>
    <PMID>17032986</PMID>
  </reference>
  <reference>
    <citation>Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007 Feb;156(2):271-6.</citation>
    <PMID>17223866</PMID>
  </reference>
  <reference>
    <citation>Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999 Dec 21-28;100(25):2473-6.</citation>
    <PMID>10604883</PMID>
  </reference>
  <reference>
    <citation>Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009 Oct;23 Suppl 2:1-70. doi: 10.1111/j.1468-3083.2009.03389.x. Erratum in: J Eur Acad Dermatol Venereol. 2010 Jan;24(1):117-8.</citation>
    <PMID>19712190</PMID>
  </reference>
  <reference>
    <citation>Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22;305(24):2525-31. doi: 10.1001/jama.2011.878.</citation>
    <PMID>21693740</PMID>
  </reference>
  <reference>
    <citation>Jensterle M, Janez A, Mlinar B, Marc J, Prezelj J, Pfeifer M. Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol. 2008 Jun;158(6):793-801. doi: 10.1530/EJE-07-0857. Epub 2008 Mar 5.</citation>
    <PMID>18322300</PMID>
  </reference>
  <reference>
    <citation>Mourão-Júnior CA, Sá JR, Guedes OM, Dib SA. Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin. Braz J Med Biol Res. 2006 Apr;39(4):489-94. Epub 2006 Apr 3.</citation>
    <PMID>16612472</PMID>
  </reference>
  <reference>
    <citation>Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6):253-70. doi: 10.1042/CS20110386. Review.</citation>
    <PMID>22117616</PMID>
  </reference>
  <reference>
    <citation>Hadi NR, Al-Amran FG, Swadi A. Metformin ameliorates methotrexate-induced hepatotoxicity. J Pharmacol Pharmacother. 2012 Jul;3(3):248-53. doi: 10.4103/0976-500X.99426.</citation>
    <PMID>23129960</PMID>
  </reference>
  <reference>
    <citation>Charles MA, Morange P, Eschwège E, André P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 1998 Nov;21(11):1967-72.</citation>
    <PMID>9802752</PMID>
  </reference>
  <reference>
    <citation>Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014 Jan;232(1):156-64. doi: 10.1016/j.atherosclerosis.2013.10.025. Epub 2013 Nov 5.</citation>
    <PMID>24401231</PMID>
  </reference>
  <reference>
    <citation>Glossmann H, Reider N. A marriage of two &quot;Methusalem&quot; drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. Dermatoendocrinol. 2013 Apr 1;5(2):252-63. doi: 10.4161/derm.23874. Review.</citation>
    <PMID>24194965</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>December 31, 2015</last_update_submitted>
  <last_update_submitted_qc>December 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Dr. Sunil Dogra</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Coal Tar</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

